MD-18
1 paper studies it5 findings
Across all fields, 1 paper: 1 trial in people
- 1 lab
- Human trial1
Outcomes
5Alanine aminotransferase
downin humans1
1 study
Alanine aminotransferase
downin humans1
MD-18 decreases alanine aminotransferase in humans.
“MD-18 significantly reduced ALT with no effect on other liver enzymes”
Human trialsubcutaneous7 daysn = 35
Results of Phase 1a Trial of MD-18, a Specific PTP-1B Inhibitor
ADA Scientific Sessions 2026 abstract
Total cholesterol
downin humans1
1 study
Total cholesterol
downin humans1
MD-18 decreases total cholesterol in humans (~10 mg/dL (p<0.005)).
“reduced LDL- and total cholesterol by ~10 mg/dL (p<0.005)”
Human trialsubcutaneous7 daysn = 35
Results of Phase 1a Trial of MD-18, a Specific PTP-1B Inhibitor
ADA Scientific Sessions 2026 abstract
Insulin
downin humans1
1 study
Insulin
downin humans1
MD-18 decreases insulin in humans (p=0.02).
“driven by decreased insulin (p=0.02)”
Human trialsubcutaneous7 daysn = 35
Results of Phase 1a Trial of MD-18, a Specific PTP-1B Inhibitor
ADA Scientific Sessions 2026 abstract
HOMA2-IR
downin humans1
1 study
HOMA2-IR
downin humans1
MD-18 decreases HOMA2-IR in humans (p<0.03).
“improvements in insulin sensitivity (HOMA2IR)(p<0.03) 7-days following a single dose that was driven by decreased insulin (p=0.02)”
Human trialsubcutaneous7 daysn = 35
Results of Phase 1a Trial of MD-18, a Specific PTP-1B Inhibitor
ADA Scientific Sessions 2026 abstract
Appetite
downin humans1
1 study
Appetite
downin humans1
MD-18 decreases appetite in humans (p=0.034).
“MD-18 treatment resulted in significant appetite suppression (p=0.034)”
Human trialsubcutaneous7 daysn = 35
Results of Phase 1a Trial of MD-18, a Specific PTP-1B Inhibitor
ADA Scientific Sessions 2026 abstract